🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

493 results for “Regeneron UK Limited” Clear

  1. REGN13335

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  2. REGN1400

    Regeneron UK Limited

    Cancer

    phase 1 small molecule completed

    1 trial

  3. REGN14284

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  4. REGN1500

    Regeneron UK Limited

    Hypertriglyceridemia

    phase 1 small molecule completed

    1 trial

  5. REGN1500

    Regeneron UK Limited

    Metabolic Disorders

    phase 1 small molecule completed

    1 trial

  6. REGN15160 (IV)

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  7. REGN17092

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  8. REGN1908-1909

    Regeneron UK Limited

    Allergy

    phase 1 small molecule completed

    2 trials

  9. REGN2009

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. REGN20423

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule active

    1 trial

  11. REGN20934

    Regeneron UK Limited

    Overweight or Obesity

    phase 1 small molecule active

    1 trial

  12. REGN2176-3

    Regeneron UK Limited

    Neovascular Wet Age-related Macular Degeneration (AMD)

    phase 1 small molecule completed

    1 trial

  13. REGN22044

    Regeneron UK Limited

    Healthy Volunteer

    phase 1 small molecule active

    1 trial

  14. REGN2222

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  15. REGN2222(SAR438584)

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  16. REGN2477

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  17. REGN2810

    Regeneron UK Limited

    Recurrent Squamous Cell Carcinoma of Head

    phase 1 small molecule completed

    1 trial

  18. REGN2810

    Regeneron UK Limited

    Melanoma

    phase 1 small molecule completed

    1 trial

  19. REGN2810

    Regeneron UK Limited

    Advanced Malignancies

    phase 1 small molecule terminated

    1 trial

  20. REGN3470-3471-3479

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  21. REGN3500

    Regeneron UK Limited

    Asthma

    phase 1 small molecule completed

    1 trial

  22. REGN3500

    Regeneron UK Limited

    Asthma, Allergic

    phase 1 small molecule completed

    1 trial

  23. REGN3500

    Regeneron UK Limited

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  24. REGN3767

    Regeneron UK Limited

    Malignancies

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources